The Clinical Features of Non-alcoholic Fatty Liver Disease and Its Risked Factors in Patients with Chronic Heart Failure

Rong SU; Ling LIN; Yuan ZHAO; Ailing YANG; Mingguo ZHANG; Hu ZHANG; Guoyu MA

Article Contents

Article Navigation > Journal of Kunming Medical University > 2025 > Corrected proof

Rong SU, Ling LIN, Yuan ZHAO, Ailing YANG, Mingguo ZHANG, Hu ZHANG, Guoyu MA. The Clinical Features of Non-alcoholic Fatty Liver Disease and Its Risked Factors in Patients with Chronic Heart Failure[J]. Journal of Kunming Medical University.

Citation:

PDF( 741 KB)

The Clinical Features of Non-alcoholic Fatty Liver Disease and Its Risked Factors in Patients with Chronic Heart Failure

1.
Department of Geriatric Cardiology，The First Affiliated Hospital of Kunming Medical University，Kunming Yunnan 650032
2.
Department of Cardiology，Lijiang People’s Hospital，Lijiang Yunnan 674100
3.
Department of Cancer Prevention and Control，The Third Affiliated Hospital of Kunming Medical University，Yunnan Cancer Hospital，Peking University Cancer Hospital Yunnan，Kunming Yunnan 650118，China

Received Date: 2024-12-13
Available Online: 2025-08-12

Abstract

Abstract

Objective To assess the prevalence and clinical features of nonalcoholic fatty liver disease （NAFLD） and its risk factors in patients with CHF, so as to provide the reference for early identification of NAFLD. Methods The data from 1120 CHF patients aged 14～89 was collected, including the general demographic information （age, gender, smoking status, height, weight, BMI, etc.）, clinical diagnosis and treatment data （blood pressure, NYHA heart function classification, blood biochemical indicators, etc.）, and medication use status. SPSS 27.0 was applied to analyze the clinical characteristics of CHF combined with NAFLD, and binary multivariate logistic regression was used to analyze the independent risk factors of CHF combined with NAFLD. Results Among the 1120 patients, 637 （56.9%） were male and 483 （43.1%） were female. The prevalence of CHF patients with NAFLD was 25.0%. The results of univariate analysis showed that the weight of NAFLD patients BMI, systolic blood pressure, diastolic blood pressure, FPG, UA, left room expansion ratio, ALT, CHO, TG, obesity rate, hyperuricemia rate and β-blocker usage rate were all higher than those of non NAFLD patients. The age, BNP, HDL and ACEI/ARB/ARNI usage rate of NAFLD patients were lower than those of non NAFLD patients （all P < 0.05）. Logistic regression analysis showed that age （OR = 0.988）, FPG （OR = 1.099）, overweight （OR = 3.497） and obesity （OR = 9.193） were independent risk factors for CHF patients with NAFLD. Conclusion NAFLD may be a common complication in CHF patients, especially those who are young, have high FPG, overweight and obese. In the clinical practice, NAFLD screening, evaluation and management should be focused on CHF patients who are young, have high fasting blood sugar, overweight, and obese.
- Chronic heart failure,
- Non-alcoholic fatty liver disease,
- BMI,
- Type 2 diabetes

FullText(HTML)

References(24)

References

[1]	Wang H,Chai K,Du M,et al. Prevalence and incidence of heart failure among urban patients in China: A national population-based analysis[J]. Circ Heart Fail,2021,14(10):e008406. doi: 10.1161/CIRCHEARTFAILURE.121.008406
[2]	侯银静,秦明照. 老年慢性心力衰竭合并共病的管理[J]. 中国实用内科杂志,2023,43(8):628-633.
[3]	中华医学会心血管病学分会,中国医师协会心血管内科医师分会,中国医师协会心力衰竭专业委员会,等. 中国心力衰竭诊断和治疗指南2024[J]. 中华心血管病杂志,2024,52(3):235-275. doi: 10.3760/cma.j.cn112148-20231101-00405
[4]	Riazi K,Azhari H,Charette JH,et al. The prevalence and incidence of NAFLD worldwide: A systematic review and meta-analysis[J]. Lancet Gastroenterol Hepatol,2022,7(9):851-861. doi: 10.1016/S2468-1253(22)00165-0
[5]	彭琳瑞,王柳,杨晓玲,等. 非酒精性脂肪性肝病的管理[J]. 中国实用内科杂志,2023,43(12):1028-1030.
[6]	Duell PB,Welty FK,Miller M,et al. Nonalcoholic fatty liver disease and cardiovascular risk: A scientific statement from the American Heart Association[J]. Arterioscler Thromb Vasc Biol,2022,42(6):e168-e185.
[7]	中华人民共和国国家卫生健康委员会医政司. 肥胖症中国诊疗指南(2024年版)[J]. 协和医学杂志,2025,16(1):90-108.
[8]	中华医学会肝病学分会. 代谢相关(非酒精性)脂肪性肝病防治指南(2024 年版)[J]. 中华肝脏病杂志,2024,32(5):418-434.
[9]	Stefan N,Cusi K. A global view of the interplay between non-alcoholic fatty liver disease and diabetes[J]. Lancet Diabetes Endocrinol,2022,10(4):284-296. doi: 10.1016/S2213-8587(22)00003-1
[10]	Liang Y,Chen H,Liu Y,et al. Association of MAFLD with diabetes,chronic kidney disease,and cardiovascular disease: A 4.6-year cohort study in China[J]. J Clin Endocrinol Metab,2022,107(1):88-97. doi: 10.1210/clinem/dgab641
[11]	Kanwal F,Shubrook J H,Younossi Z,et al. Preparing for the NASH epidemic: A call to action[J]. Gastroenterology,2021,161(3):1030-1042. doi: 10.1053/j.gastro.2021.04.074
[12]	Canada JM,Abbate A,Collen R,et al. Relation of hepatic fibrosis in nonalcoholic fatty liver disease to left ventricular diastolic function and exercise tolerance[J]. Am J Cardiol,2019,123(3):466-473. doi: 10.1016/j.amjcard.2018.10.027
[13]	Miller A,McNamara J,Hummel S L,et al. Prevalence and staging of non-alcoholic fatty liver disease among patients with heart failure with preserved ejection fraction[J]. Sci Rep,2020,10(1):12440. doi: 10.1038/s41598-020-69013-y
[14]	Zhang Z,Wang P,Guo F,et al. Chronic heart failure in patients with nonalcoholic fatty liver disease: Prevalence,clinical features,and relevance[J]. J Int Med Res,2018,46(9):3959-3969. doi: 10.1177/0300060518782780
[15]	Chew N W S,Ng C H,Tan D J H,et al. The global burden of metabolic disease: Data from 2000 to 2019[J]. Cell Metab,2023,35(3):414-428. doi: 10.1016/j.cmet.2023.02.003
[16]	Younossi Z M,Tampi R,Priyadarshini M,et al. Burden of illness and economic model for patients with nonalcoholic steatohepatitis in the United States[J]. Hepatology,2019,69(2):564-572. doi: 10.1002/hep.30254
[17]	Lu R,Liu Y,Hong T. Epidemiological characteristics and management of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis in China: A narrative review[J]. Diabetes Obes Metab,2023,25(Suppl 1):13-26.
[18]	Quek J,Chan K E,Wong Z Y,et al. Global prevalence of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in the overweight and obese population: A systematic review and meta-analysis[J]. Lancet Gastroenterol Hepatol,2023,8(1):20-30. doi: 10.1016/S2468-1253(22)00317-X
[19]	Pan XF,Wang L,Pan A. Epidemiology and determinants of obesity in China [J]. Lancet Diabetes Endocrinol,2021,9 (6): 373‑392.
[20]	DiStefano J K,Gerhard G S. NAFLD in normal weight individuals[J]. Diabetol Metab Syndr,2022,14(1):45. doi: 10.1186/s13098-022-00814-z
[21]	Lee S W,Lee T Y,Yang S S,et al. Risk factors and metabolic abnormality of patients with non‑alcoholic fatty liver disease: Either non‑obese or obese Chinese population[J]. Hepatobiliary Pancreat Dis Int,2018,17 (1): 45‑48.
[22]	Ng C H,Wong Z Y,Chew N W S,et al. Hypertension is prevalent in non-alcoholic fatty liver disease and increases all-cause and cardiovascular mortality[J]. Front Cardiovasc Med,2022,9:942753. doi: 10.3389/fcvm.2022.942753
[23]	Toh J Z K,Pan X H,Tay P W L,et al. A Meta-analysis on the global prevalence,risk factors and screening of coronary heart disease in nonalcoholic fatty liver disease[J]. Clin Gastroenterol Hepatol,2022,20(11):2462-2473. doi: 10.1016/j.cgh.2021.09.021
[24]	Ayada I,van Kleef L A,Zhang H,et al. Dissecting the multifaceted impact of statin use on fatty liver disease: A multidimensional study[J]. EBio Medicine,2023,1(87):1-11.

Relative Articles(20)

Relative Articles

[1]	Ying QIAN, Jizhuo YANG, Juan HUANG, Kedi YUAN, Junyi LIU, Yuemei FENG, Jianzhong YIN. The Role of Mitochondrial Function in Adipose Tissue in Obesity. Journal of Kunming Medical University, doi: 10.12259/j.issn.2095-610X.S20250701
[2]	Peng DING, Jia LI, Xiaodan ZHAO, Jie ZHAO, Changrong MIAO. Protective Effect of MiR-193a-5p on Cardiac Function in Rats with Chronic Heart Failure by Regulating IL-33/ST2 Signaling Pathway. Journal of Kunming Medical University, doi: 10.12259/j.issn.2095-610X.S20250506
[3]	Xinlin ZHU, Yanan WU, Qi MENG, Qianzi YANG, Yuanbiao LI, Junheng TAO, Mengyang HE. Influence of Medication Compliance of Type 2 Diabetes Chronic Disease Management Patients in Two Communities of Kunming on Disease Control. Journal of Kunming Medical University, doi: 10.12259/j.issn.2095-610X.S20240312
[4]	Yuanyuan LI, Yaxian SONG, Yushan XU, Xiaofu ZENG, Hui YUAN, Zhao XU, Yan JIANG. The Association of Intestinal Flora Metabolite TMAO with Non-alcoholic Fatty Liver Disease. Journal of Kunming Medical University, doi: 10.12259/j.issn.2095-610X.S20240210
[5]	Hang CHEN, Qi CUI, Minshan HUANG, Jianjun LIU, Lanqing MA. Research Progress of miRNA in Non-alcoholic Fatty Liver Disease. Journal of Kunming Medical University, doi: 10.12259/j.issn.2095-610X.S20240101
[6]	Xuemin ZHANG, Yunfen TIAN. Role of Abnormal Bile Acid Metabolism in the Development of Non-alcoholic Fatty Liver Disease. Journal of Kunming Medical University, doi: 10.12259/j.issn.2095-610X.S20231125
[7]	Lu LI, Yunfen TIAN. Research Progress on Intestinal Microflora and Non-alcoholic Fatty Liver Disease in Children. Journal of Kunming Medical University, doi: 10.12259/j.issn.2095-610X.S20230708
[8]	Ling NIU, Boyi LI, Cuijuan MIAO, Cheng ZHANG, Yan TANG, Fang LIU, Rong MA. Relationship between Leptin，Uric Acid，and Obesity in Type 2 Diabetes Mellitus. Journal of Kunming Medical University, doi: 10.12259/j.issn.2095-610X.S20231121
[9]	Yongrui YANG, Liyuan WANG, Haiwen LI, Zhirong ZHAO, Rui PU, Guishuai WU, Shude LI. Scutellarin Ameliorates Liver Fibrosis in Nonalcoholic Fatty Liver Disease by Inhibiting NOX Expression. Journal of Kunming Medical University, doi: 10.12259/j.issn.2095-610X.S20220721
[10]	Yong-fang XU, Na WU, Yue-xin HU, Yong-mei ZHAO, Shao-ding ZHENG, Ling WEI, Si-jia ZHENG, Jian-jun LIU. Therapeutic Effect of GW7647 on Non-alcoholic Fatty Liver Disease in Rats. Journal of Kunming Medical University, doi: 10.12259/j.issn.2095-610X.S20210804
[11]	Jia-dai TANG, Lin XIE, Hong-li SONG, Jiao-jiao CHEN. Correlation between Metabolic Syndrome and the Occurrence and Development of Gastric Cancer. Journal of Kunming Medical University, doi: 10.12259/j.issn.2095-610X.S20211130
[12]	Lu YANG, Wen-jun SHI, Ling ZHAO, Shi-gang DU, Pei-qi CHEN, Ting-yu KE. The Correlation between Visceral Fat Area in Patients with Type 2 Diabetes and Obesity and Glycolipid Metabolism. Journal of Kunming Medical University, doi: 10.12259/j.issn.2095-610X.S20210932
[13]	Yun ZHOU, Liu YANG, Xue-qing NA. Correlation Between Obesity and Oxygen Reserve during Induction of General Anesthsia. Journal of Kunming Medical University, doi: 10.12259/j.issn.2095-610X.S20201130
[14]	Tang Juan , Nian Xin . . Journal of Kunming Medical University,
[15]	Li Xiao Hong , Ma Run Mei , Chen Zhuo . . Journal of Kunming Medical University,
[16]	Han Wen Ju , Niu Ben , Liang Yun, Duan Xiao Yan , Su Heng , Xue Yuan Ming . The Relationship between Thyroid Hormone and Purine Metabolism and Body Weight in Patients with Type II Diabetes and Normal Thyroid Function. Journal of Kunming Medical University,
[17]	Luo Yong Li . Clinical Assessment on the Safety of Cardiac Rehabilitation for the Elderly Patients with Chronic Heart Failure. Journal of Kunming Medical University,
[18]	Liu Rong . . Journal of Kunming Medical University,
[19]	Su Mei Hui . . Journal of Kunming Medical University,
[20]	Li Xian Li . . Journal of Kunming Medical University,